{"preliminary_commentary":{"by_channel":{"youtube":2,"podcast":2,"x_thread":1,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["bleximenib"]],"indication":null,"name":"cAMeLot-2","nct_id":"NCT06852222","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=camelot-2-nct06852222. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"cAMeLot-2","arms":[{"description":"Participants with acute myeloid leukemia (AML) will receive bleximenib in combination with venetoclax (VEN) and azacitidine (AZA) for 28-days treatment cycles and treatment will continue until progression or unacceptable toxicity.","label":"Arm A: Bleximenib and Venetoclax (VEN) + Azacitidine (AZA)","type":"EXPERIMENTAL"},{"description":"Participants with AML will receive placebo in combination with VEN and AZA for 28-days treatment cycles, and treatment will continue until progression or unacceptable toxicity.","label":"Arm B: Placebo and Venetoclax (VEN) + Azacitidine (AZA)","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-08-15","type":"ESTIMATED"},"conditions":["Leukemia, Myeloid, Acute"],"enrollment":{"count":600,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Bleximenib","otherNames":["JNJ-75276617"],"type":"DRUG"},{"name":"Venetoclax (VEN)","otherNames":[],"type":"DRUG"},{"name":"Azacitidine (AZA)","otherNames":[],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-25","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-06-22","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Percentage of Participants who Achieve Complete Remission (CR)","timeFrame":"Up to 4 years and 1 month"},{"measure":"Overall Survival (OS)","timeFrame":"Up to 4 years and 1 month"}],"references":[],"start_date":{"date":"2025-06-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)","url":"https://clinicaltrials.gov/study/NCT06852222"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/camelot-2-nct06852222"}